The absolute GHK-Cu contraindications, like Wilsons disease or active cancer, apply regardless of the delivery method because the peptide can still have systemic effects
The value of the combo lies in **mechanistic divergence coupled with vascular convergence**: BPC-157 covers local cytoprotection and the gut-tendon axis, TB-500 covers systemic cell migration and stem-cell mobilization, and both converge on the neoangiogenesis required for deep tissue regeneration
It pulses, primarily during deep sleep, and those pulses are regulated in part by estrogen
GLP-1 medications address that specific bottleneck
Mild side effects are rare and usually occur only if the dosage exceeds the suggested amount
*Important notice: medRxiv publishes preliminary scientific reports that are not peer-reviewed and, therefore, should not be regarded as conclusive, guide clinical practice/health-related behavior, or treated as established information